Advertisement

Breast Cancer Research and Treatment

, Volume 172, Issue 2, pp 247–263 | Cite as

Racial disparities in chemotherapy administration for early-stage breast cancer: a systematic review and meta-analysis

  • Angela K. Green
  • Emeline M. Aviki
  • Konstantina Matsoukas
  • Sujata Patil
  • Deborah Korenstein
  • Victoria Blinder
Review
  • 114 Downloads

Abstract

Purpose

We conducted a systematic review and meta-analysis to measure the extent to which race is associated with delayed initiation or receipt of inadequate chemotherapy among women with early-stage breast cancer.

Methods

We performed a systematic search of all articles published from January 1987 until June 2017 within four databases: PubMed/Medline, EMBASE, CINAHL, and Cochrane CENTRAL. Eligible studies were US-based and examined the influence of race on chemotherapy delays, cessation, or dose reductions among women with stage I, II, or III breast cancer. Data were pooled using a random effects model.

Results

A total of twelve studies were included in the quantitative analysis. Blacks were significantly more likely than whites to have delays to initiation of adjuvant therapy of 90 days or more (OR 1.41, 95% CI 1.06–1.87; X² = 31.05, p < 0.00001; I² = 90%). There was no significant association between race and chemotherapy dosing. Due to overlap between studies assessing the relationship between race and completion of chemotherapy, we conducted two separate analyses. Black patients were significantly more likely to discontinue chemotherapy, however, this was no longer statistically significant when larger numbers of patients with more advanced (stage III) breast cancer were included.

Conclusions

These results suggest that black breast cancer patients experience clinically relevant delays in the initiation of adjuvant chemotherapy more often than white patients, which may in part explain the increased mortality observed among black patients.

Keywords

Race Disparities Chemotherapy administration Delays Relative dose intensity 

Notes

Acknowledgements

Nina A. Bickell MD MPH, Dawn L. Hershman MD MS, and Joseph Unger, PhD MS for provision of data used in the meta-analysis.

Compliance with ethical standards

Conflict of interest

All authors declared that they have no conflict of interest.

Ethical Approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Supplementary material

10549_2018_4909_MOESM1_ESM.doc (86 kb)
Supplementary material 1 (DOC 86 KB)

References

  1. 1.
    Yu KD, Huang S, Zhang JX, Liu GY, Shao ZM (2013) Association between delayed initiation of adjuvant CMF or anthracycline-based chemotherapy and survival in breast cancer: a systematic review and meta-analysis. BMC Cancer 13:240CrossRefGoogle Scholar
  2. 2.
    Biagi JJRM, King WD, Kong W, Booth CM, Mackillop WJ (2011) The effect of delay in time to adjuvant chemotherapy (TTAC) on survival in breast cancer (BC): a systematic review and meta-analysis. J Clin Oncol 29(15):1128–1128CrossRefGoogle Scholar
  3. 3.
    Chavez-MacGregor M, Clarke CA, Lichtensztajn DY, Giordano SH (2016) Delayed initiation of adjuvant chemotherapy among patients with breast cancer. JAMA Oncol 2(3):322–329CrossRefGoogle Scholar
  4. 4.
    Hryniuk W, Bush H (1984) The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 2(11):1281–1288CrossRefGoogle Scholar
  5. 5.
    Wood WC, Budman DR, Korzun AH et al (1994) Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 330(18):1253–1259CrossRefGoogle Scholar
  6. 6.
    Budman DR, Berry DA, Cirrincione CT et al (1998) Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst 90(16):1205–1211CrossRefGoogle Scholar
  7. 7.
    Pronzato P, Campora E, Amoroso D et al (1989) Impact of administration-related factors on outcome of adjuvant chemotherapy for primary breast cancer. Am J Clin Oncol 12(6):481–485CrossRefGoogle Scholar
  8. 8.
    Hryniuk W, Levine MN (1986) Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol 4(8):1162–1170CrossRefGoogle Scholar
  9. 9.
    Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C (1995) Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 332(14):901–906CrossRefGoogle Scholar
  10. 10.
    Wheeler SB, Reeder-Hayes KE, Carey LA (2013) Disparities in breast cancer treatment and outcomes: Biological, social, and health system determinants and opportunities for research. Oncologist 18(9):986–993CrossRefGoogle Scholar
  11. 11.
    Hershman D, Weinberg M, Rosner Z et al (2003) Ethnic neutropenia and treatment delay in African American women undergoing chemotherapy for early-stage breast cancer. J Natl Cancer Inst 95(20):1545–1548CrossRefGoogle Scholar
  12. 12.
    Bain BJ (1996) Ethnic and sex differences in the total and differential white cell count and platelet count. J Clin Pathol 49(8):664–666CrossRefGoogle Scholar
  13. 13.
    Penner LA, Eggly S, Griggs JJ, Underwood W III, Orom H, Albrecht TL (2012) Life-threatening disparities: the treatment of black and white cancer patients. J Soc Issues 68(2):328–357CrossRefGoogle Scholar
  14. 14.
    Green AR, Carney DR, Pallin DJ et al (2007) Implicit bias among physicians and its prediction of thrombolysis decisions for black and white patients. J Genet Intern Med 22(9):1231–1238CrossRefGoogle Scholar
  15. 15.
    O’Malley AS, Sheppard VB, Schwartz M, Mandelblatt J (2004) The role of trust in use of preventive services among low-income African-American women. Prev Med 38(6):777–785CrossRefGoogle Scholar
  16. 16.
    Griggs JJ, Liu Y, Sorbero ME, Jagielski CH, Maly RC (2014) Adjuvant chemotherapy dosing in low-income women: the impact of Hispanic ethnicity and patient self-efficacy. Br Cancer Res Treat 144(3):665–672CrossRefGoogle Scholar
  17. 17.
    Griggs JJ, Culakova E, Sorbero ME et al (2007) Effect of patient socioeconomic status and body mass index on the quality of breast cancer adjuvant chemotherapy. J Clin Oncol 25(3):277–284CrossRefGoogle Scholar
  18. 18.
    Griggs JJ, Sorbero ME, Stark AT, Heininger SE, Dick AW (2003) Racial disparity in the dose and dose intensity of breast cancer adjuvant chemotherapy. Breast Cancer Res Treat 81(1):21–31CrossRefGoogle Scholar
  19. 19.
    Hershman DL, Unger JM, Barlow WE et al (2009) Treatment quality and outcomes of African American versus white breast cancer patients: retrospective analysis of southwest oncology studies S8814/S8897. J Clin Oncol 27(13):2157–2162CrossRefGoogle Scholar
  20. 20.
    Lyman GH, Dale DC, Crawford J (2003) Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol 21(24):4524–4531CrossRefGoogle Scholar
  21. 21.
    Hershman D, McBride R, Jacobson JS et al (2005) Racial disparities in treatment and survival among women with early-stage breast cancer. J Clin Oncol 23(27):6639–6646CrossRefGoogle Scholar
  22. 22.
    Simon MS, Lamerato L, Krajenta R et al (2012) Racial differences in the use of adjuvant chemotherapy for breast cancer in a large urban integrated health system. Int J Br cancer 2012:453985Google Scholar
  23. 23.
    McLaughlin JM, Anderson RT, Ferketich AK, Seiber EE, Balkrishnan R, Paskett ED (2012) Effect on survival of longer intervals between confirmed diagnosis and treatment initiation among low-income women with breast cancer. J Clin Oncol 30(36):4493–4500CrossRefGoogle Scholar
  24. 24.
    Gwyn K, Bondy ML, Cohen DS et al (2004) Racial differences in diagnosis, treatment, and clinical delays in a population-based study of patients with newly diagnosed breast carcinoma. Cancer 100(8):1595–1604CrossRefGoogle Scholar
  25. 25.
    Gorin SS, Heck JE, Cheng B, Smith SJ (2006) Delays in breast cancer diagnosis and treatment by racial/ethnic group. Arch Intern Med 166(20):2244–2252CrossRefGoogle Scholar
  26. 26.
    Vandergrift JL, Niland JC, Theriault RL et al (2013) Time to adjuvant chemotherapy for breast cancer in National Comprehensive Cancer Network institutions. J Natl Cancer Inst 105(2):104–112CrossRefGoogle Scholar
  27. 27.
    Hershman DL, Wang X, McBride R, Jacobson JS, Grann VR, Neugut AI (2006) Delay of adjuvant chemotherapy initiation following breast cancer surgery among elderly women. Breast Cancer Res Treat 99(3):313–321CrossRefGoogle Scholar
  28. 28.
    Fedewa SA, Ward EM, Stewart AK, Edge SB (2010) Delays in adjuvant chemotherapy treatment among patients with breast cancer are more likely in African American and Hispanic populations: a national cohort study 2004–2006. J Clin Oncol 28(27):4135–4141CrossRefGoogle Scholar
  29. 29.
    Nurgalieva ZZ, Franzini L, Morgan RO, Vernon SW, Liu CC, Du XL (2013) Impact of timing of adjuvant chemotherapy initiation and completion after surgery on racial disparities in survival among women with breast cancer. Med Oncol 30(1):419CrossRefGoogle Scholar
  30. 30.
    de Gagliato M, Gonzalez-Angulo AM, Lei X et al (2014) Clinical impact of delaying initiation of adjuvant chemotherapy in patients with breast cancer. J Clin Oncol 32(8):735–744CrossRefGoogle Scholar
  31. 31.
    Reyes SA, King TA, Fei K, Franco R, Bickell NA (2016) Factors affecting the completion of adjuvant chemotherapy in early-stage breast cancer. Ann Surg Oncol 23(5):1537–1542CrossRefGoogle Scholar
  32. 32.
    Yi M, Mittendorf EA, Cormier JN et al (2011) Novel staging system for predicting disease-specific survival in patients with breast cancer treated with surgery as the first intervention: time to modify the current American Joint Committee on Cancer staging system. J Clin Oncol 29(35):4654–4661CrossRefGoogle Scholar
  33. 33.
    Jemal A, Robbins AS, Lin CC et al (2018) Factors that contributed to black-white disparities in survival among nonelderly women with breast cancer between 2004 and 2013. J Clin Oncol 36(1):14–24CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Memorial Sloan Kettering Cancer CenterNew YorkUSA

Personalised recommendations